Evidence map›Paper›PMID 32605805›Full record

ReviewTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2020

Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data.

José Luis Arroyo, Eva Martínez, Cristina Amunárriz, Carmen Muñoz, Iñigo Romón, Ignacio Álvarez, José María García

Open access · bronzeAbstract readReview
In one paragraph

Review in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

José Luis ArroyoBanco de Sangre y Tejidos de Cantabria, Liencres, Spain. Electronic address: director@bscan.org.
Eva MartínezServicio de Transfusión, Hospital Universitario Central de Asturias, Oviedo, Spain.
Cristina AmunárrizBanco de Sangre y Tejidos de Cantabria, Liencres, Spain.
Carmen MuñozCentro Comunitario de Sangre y Tejidos de Asturias, Oviedo, Spain.
Iñigo RomónServicio de Transfusión, Hospital Marqués de Valdecilla, Santander, Spain.
Ignacio ÁlvarezMacoPharma, Tourcoing, France.
José María GarcíaServicio de Transfusión, Hospital Universitario Central de Asturias, Oviedo, Spain.
Banc de Sang i Teixits · ESHospital Universitario Central de Asturias · ESMacopharma (France) · FRMarqués de Valdecilla University Hospital · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTherapeutic plasma exchange (TPE) is the first-line treatment for acute thrombotic thrombocytopenic purpura (TTP). Methylene blue-plasma (MBP) has been used for over 20 years, but its efficacy in this setting remains controversial. PATIENTS AND

methodsthis is a comparative analysis of the experience of two Centres, with different plasma products, to evaluate their efficacy in TTP. One centre used quarantine plasma (QP), and MBP the other. We performed a retrospective longitudinal study, analysing the clinical files of TTP patients of a 13-year data evaluation period. Duration of treatment and transfusion parameters, medical record, laboratory testing, concomitant medication, and survival rate, were assessed for every episode.

resultsDuring the study period, 12 (55.5 %) and 10 (45.5 %) new cases were treated with QP and MBP, respectively. There were no significant differences between the mean numbers of TPE processes, days elapsed from diagnosis to TPE, and plasma volume transfused. The QP TPE episodes of treatment were significantly associated with an increased time to recovery compared with MBP episodes of treatment (p = 0.004).

conclusionMBP was as effective as QP in the treatment of TTP patients. Since recovery was more favourable when MBP was used, we consider MBP remains a suitable alternative to treat TTP patients.

Indexed as

Acute DiseaseAdolescentAdultAgedChildChild, PreschoolFemaleHumansLongitudinal StudiesMaleMethylene BlueMiddle AgedPlasmaPurpura, Thrombotic ThrombocytopenicYoung AdultMethylene BlueMethylene blue-photoinactivated plasmaPathogen reductionQuarantine plasmaTherapeutic plasma exchangeThrombotic thrombocytopenic purpura

Identifiers

PMID32605805
PMCPMC7152885
OpenAlexW3015927160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.